During the last session, Codexis Inc. (NASDAQ:CDXS)’s traded shares were 1.44 million, with the beta value of the company hitting 1.69. At the end of the trading day, the stock’s price was $7.78, reflecting an intraday gain of 3.60% or $0.27. The 52-week high for the CDXS share is $42.01, that puts it down -439.97 from that peak though still a striking 20.95% gain since the share price plummeted to a 52-week low of $6.15. The company’s market capitalization is $565.84M, and the average intraday trading volume over the past 10 days was 1.16 million shares, and the average trade volume was 1.16 million shares over the past three months.
Codexis Inc. (CDXS) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 1.60. CDXS has a Sell rating from 0 analyst(s) out of 8 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 8 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.13.
Codexis Inc. (NASDAQ:CDXS) trade information
Codexis Inc. (CDXS) registered a 3.60% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 3.60% in intraday trading to $7.78 this Wednesday, 08/03/22, hitting a weekly high. The stock’s 5-day price performance is 1.83%, and it has moved by -35.17% in 30 days. Based on these gigs, the overall price performance for the year is -64.00%. The short interest in Codexis Inc. (NASDAQ:CDXS) is 5.53 million shares and it means that shorts have 4.03 day(s) to cover.
The consensus price target of analysts on Wall Street is $22.25, which implies an increase of 65.03% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $12.00 and $39.00 respectively. As a result, CDXS is trading at a discount of -401.29% off the target high and -54.24% off the low.
Codexis Inc. (CDXS) estimates and forecasts
Statistics show that Codexis Inc. has outperformed its competitors in share price, compared to the industry in which it operates. Codexis Inc. (CDXS) shares have gone down -62.42% during the last six months, with a year-to-date growth rate more than the industry average at 30.30% against 1.00. Yet analysts are ramping up their growth forecast for the fiscal year 2022. Revenue is predicted to shrink -85.70% this quarter and then drop -733.30% in the quarter after that. In the rating firms’ projections, revenue will increase 31.40% compared to the previous financial year.
Revenue for the current quarter is expected to be $38.55 million as predicted by 8 analyst(s). Meanwhile, a consensus of 8 analyst(s) estimates revenue growth to $33.27 million by the end of Sep 2022.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -9.40%. While earnings are projected to return 18.50% in 2022, the next five years will return 15.00% per annum.
Codexis Inc. is due to release its next quarterly earnings between February 23 and February 28. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Codexis Inc. (NASDAQ:CDXS)’s Major holders
Codexis Inc. insiders own 2.65% of total outstanding shares while institutional holders control 102.87%, with the float percentage being 105.67%. Baillie Gifford and Company is the largest shareholder of the company, while 233 institutions own stock in it. As of Mar 30, 2022, the company held over 7.39 million shares (or 11.31% of all shares), a total value of $152.31 million in shares.
The next largest institutional holding, with 5.18 million shares, is of Blackrock Inc.’s that is approximately 7.94% of outstanding shares. At the market price on Mar 30, 2022, these shares were valued at $106.88 million.
Also, the Mutual Funds coming in first place with the largest holdings of Codexis Inc. (CDXS) shares are ARK ETF Tr-ARK Genomic Revolution ETF and Vanguard Total Stock Market Index Fund. Data provided on Jun 29, 2022 indicates that ARK ETF Tr-ARK Genomic Revolution ETF owns about 4.39 million shares. This amounts to just over 6.73 percent of the company’s overall shares, with a $45.95 million market value. The same data shows that the other fund manager holds slightly less at 1.8 million, or about 2.75% of the stock, which is worth about $37.07 million.